
Biomerica BMRA
$ 2.36
-1.26%
Quarterly report 2025-Q4
added 01-14-2026
Biomerica Accounts Receivables 2011-2026 | BMRA
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Biomerica
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 731 K | 947 K | 722 K | 774 K | 1.46 M | 1.77 M | 1.45 M | 800 K | 1.06 M | 969 K | 1.11 M | 1.45 M | 872 K | 1.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.77 M | 722 K | 1.09 M |
Quarterly Accounts Receivables Biomerica
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 947 K | 1.2 M | 731 K | 1.27 M | 1.33 M | 1.55 M | 947 K | 1.13 M | 1.07 M | 1.43 M | 722 K | 755 K | 850 K | 932 K | 774 K | 1.16 M | 1.13 M | 772 K | 1.46 M | 1.46 M | 1.61 M | 1.58 M | 1.77 M | 1.77 M | 1.28 M | 859 K | 1.45 M | 1.45 M | 1.26 M | 1.01 M | 800 K | 800 K | 1.06 M | 1.05 M | 1.06 M | 1.06 M | 1.14 M | 969 K | 969 K | 969 K | 1.17 M | 1.21 M | 1.11 M | 1.11 M | 564 K | 788 K | 1.45 M | 1.45 M | 822 K | 903 K | 872 K | 872 K | 1.51 M | 1.37 M | 1.2 M | 1.2 M | 1.13 M | 865 K | 747 K | 747 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.77 M | 564 K | 1.11 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
173 K | $ 3.05 | -1.62 % | $ 99 K | ||
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 34.5 | 2.16 % | $ 371 M | ||
|
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | ||
|
BioNano Genomics
BNGO
|
4.75 M | $ 1.24 | -15.65 % | $ 1.58 M | ||
|
Castle Biosciences
CSTL
|
51.2 M | $ 39.73 | 1.44 % | $ 1.1 B | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
304 K | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
3.54 B | $ 219.15 | -0.14 % | $ 160 B | ||
|
Exact Sciences Corporation
EXAS
|
249 M | $ 102.44 | 0.13 % | $ 19 B | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | ||
|
Fulgent Genetics
FLGT
|
69 M | $ 26.14 | -0.38 % | $ 790 M | ||
|
Guardant Health
GH
|
110 M | $ 113.64 | 2.86 % | $ 13.9 B | ||
|
DexCom
DXCM
|
974 M | $ 73.4 | -0.81 % | $ 28.3 B | ||
|
CareDx, Inc
CDNA
|
51.1 M | $ 20.69 | -0.53 % | $ 1.11 B | ||
|
DarioHealth Corp.
DRIO
|
3.16 M | $ 9.94 | -3.54 % | $ 282 M | ||
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
321 M | $ 66.97 | 0.44 % | $ 4.63 B | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
735 M | $ 145.56 | -2.76 % | $ 23.1 B | ||
|
NeoGenomics
NEO
|
151 M | $ 12.04 | -2.9 % | $ 1.52 B | ||
|
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B | ||
|
IQVIA Holdings
IQV
|
3.2 B | $ 231.17 | -1.83 % | $ 41.9 B | ||
|
Charles River Laboratories International
CRL
|
721 M | $ 210.54 | -0.57 % | $ 10.8 B | ||
|
Medpace Holdings
MEDP
|
296 M | $ 585.64 | -1.25 % | $ 18.1 B | ||
|
Personalis
PSNL
|
8.14 M | $ 9.43 | -5.42 % | $ 559 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 186.85 | 2.49 % | $ 20.7 B | ||
|
Biodesix
BDSX
|
8.6 M | $ 9.94 | 2.85 % | $ 1.29 B | ||
|
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | ||
|
Precipio
PRPO
|
1.3 M | $ 24.53 | 1.11 % | $ 31.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
1.94 B | $ 271.48 | 0.62 % | $ 22.8 B | ||
|
Mettler-Toledo International
MTD
|
687 M | $ 1 381.85 | -0.79 % | $ 29.3 B | ||
|
ICON Public Limited Company
ICLR
|
1.34 B | $ 180.78 | -2.75 % | $ 14.9 B | ||
|
IDEXX Laboratories
IDXX
|
474 M | $ 674.26 | -0.36 % | $ 55.6 B | ||
|
Agilent Technologies
A
|
1.17 B | $ 133.38 | 0.11 % | $ 40.5 B |